[go: up one dir, main page]

PL1644509T3 - Zastosowanie związanej z FAK nie-kinazy do wytwarzania leku do hamowania stenozy i restenozy - Google Patents

Zastosowanie związanej z FAK nie-kinazy do wytwarzania leku do hamowania stenozy i restenozy

Info

Publication number
PL1644509T3
PL1644509T3 PL04741142T PL04741142T PL1644509T3 PL 1644509 T3 PL1644509 T3 PL 1644509T3 PL 04741142 T PL04741142 T PL 04741142T PL 04741142 T PL04741142 T PL 04741142T PL 1644509 T3 PL1644509 T3 PL 1644509T3
Authority
PL
Poland
Prior art keywords
fak
stenosis
restenosis
kinase
medicament
Prior art date
Application number
PL04741142T
Other languages
English (en)
Inventor
Martin Laser
Christof Hauck
Jörg Strotmann
Original Assignee
Bayerische Julius Maximilians Univ Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayerische Julius Maximilians Univ Wuerzburg filed Critical Bayerische Julius Maximilians Univ Wuerzburg
Publication of PL1644509T3 publication Critical patent/PL1644509T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL04741142T 2003-07-17 2004-07-19 Zastosowanie związanej z FAK nie-kinazy do wytwarzania leku do hamowania stenozy i restenozy PL1644509T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03016259 2003-07-17
EP04741142A EP1644509B1 (en) 2003-07-17 2004-07-19 Use of fak-related non-kinase in the manufacture of a medicament for the inhibition of stenosis and restenosis
PCT/EP2004/008056 WO2005014835A1 (en) 2003-07-17 2004-07-19 Use of fak-related non-kinase in the manufacture of a medicament for the inhibition of stenosis and restenosis

Publications (1)

Publication Number Publication Date
PL1644509T3 true PL1644509T3 (pl) 2007-10-31

Family

ID=34130025

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04741142T PL1644509T3 (pl) 2003-07-17 2004-07-19 Zastosowanie związanej z FAK nie-kinazy do wytwarzania leku do hamowania stenozy i restenozy

Country Status (8)

Country Link
US (1) US20070009481A1 (pl)
EP (1) EP1644509B1 (pl)
JP (1) JP2009513556A (pl)
AT (1) ATE361370T1 (pl)
DE (1) DE602004006272T2 (pl)
ES (1) ES2286644T3 (pl)
PL (1) PL1644509T3 (pl)
WO (1) WO2005014835A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2562018A1 (en) * 2004-04-05 2005-10-20 Medivas, Llc Bioactive stents for type ii diabetics and methods for use thereof
JP5623740B2 (ja) * 2006-07-25 2014-11-12 セラドン・コーポレーション 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入
WO2015054477A1 (en) 2013-10-09 2015-04-16 The General Hospital Corporation Methods of diagnosing and treating b cell acute lymphoblastic leukemia
EP2982368A1 (en) * 2014-08-04 2016-02-10 Universität Konstanz Small molecule compounds displacing focal adhesion core components

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4509037A (en) * 1981-06-12 1985-04-02 Gould Inc. Enhanced delta modulation encoder
US4737702A (en) * 1982-06-07 1988-04-12 Norand Corporation Battery charging control system particularly for hand held device
US4998109A (en) * 1989-12-13 1991-03-05 Lechevalier Robert E Analog to digital conversion device by charge integration using delay-line time measurement
JP3039809B2 (ja) * 1990-05-31 2000-05-08 株式会社日立製作所 アナログ／ディジタル変換器、サンプリングパルス生成回路、及び電流スイッチ回路
WO1999028750A1 (en) * 1997-12-03 1999-06-10 The University Of North Carolina At Chapel Hill Frnk proteins in the treatment of tumor cells
WO2001009360A1 (en) * 1999-08-02 2001-02-08 Avigen, Inc. USE OF RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR (rAAV) FOR THE PREVENTION OF SMOOTH MUSCLE CELL PROLIFERATION IN A VASCULAR GRAFT
US20020161376A1 (en) * 2001-04-27 2002-10-31 Barry James J. Method and system for delivery of coated implants

Also Published As

Publication number Publication date
ES2286644T3 (es) 2007-12-01
EP1644509A1 (en) 2006-04-12
JP2009513556A (ja) 2009-04-02
WO2005014835A1 (en) 2005-02-17
ATE361370T1 (de) 2007-05-15
EP1644509B1 (en) 2007-05-02
DE602004006272T2 (de) 2008-01-10
US20070009481A1 (en) 2007-01-11
DE602004006272D1 (de) 2007-06-14

Similar Documents

Publication Publication Date Title
IL161335A (en) Coating of stents for preventing restenosis
ATE481058T1 (de) Dilatations- und stentablagesystem
HRP20040059B1 (en) Treatment of nail infections with no
DE50310516D1 (de) Fredericamycin-derivate
MX2007000350A (es) Stent con elementos asimetricos de longitud desigual.
MXPA02008233A (es) Compuestos de pteridina para tratamiento de psoriasis.
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
DK1432380T3 (da) Indretning baseret på nitrol med et overtræk af polyphosphazen
NO20070866L (no) Antivirale forbindelser.
GEP20094601B (en) Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes
WO2003080582A3 (de) Fredericamycin-derivate
CY1108748T1 (el) Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων
BR0211450A (pt) Método terapêutico
MXPA04003755A (es) Endoprotesis vasculares.
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
PL1644509T3 (pl) Zastosowanie związanej z FAK nie-kinazy do wytwarzania leku do hamowania stenozy i restenozy
NZ519722A (en) Treatment of diabetic ulcers
ATE364409T1 (de) Beschichtungssystem für implantate zur erhöhung der gewebsverträglichkeit
TW200628458A (en) Metasubstituted thiazolidinones, their manufacture and use as a drug
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
WO2003035048A3 (en) Methods for the treatment of osteoarthritis and compositions thereof
MX9700298A (es) Adenovirus que comprende un gen que codifica para una no sintasa.
ATE533779T1 (de) Isoliertes photoprotein mtclytin, sowie dessen verwendung
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens